Press Release
Qubit Pharmaceuticals Appoints Romain Delassus as
Chief Information Officer
Paris, June 19, 2025 - Qubit Pharmaceuticals, a deeptech company specializing in the discovery of novel drug candidates through molecular simulation and modeling accelerated by hybrid HPC and quantum computing, announces the arrival of Romain Delassus as its new Chief Information Officer.
Aged 37, Romain brings over a decade of experience in leading user-centered digital product development and impact-driven organizations, primarily in the public sector. A graduate of École Polytechnique and a Corps des Mines engineer, he began his career at ARCEP (the French regulatory authority for digital infrastructure, postal services, and press distribution), before moving to the French National Digital Council, then to the Directorate General for Enterprises within the Ministry of Economy and Finance.
In 2018, he joined the Ministry of Culture, where he spent nearly seven years. He notably led the development of the Pass Culture (with 4.7 million users and 35,000 partners), using a product approach inspired by France’s "State Startup" model. He later founded and headed the Ministry’s digital department, comprising around 100 staff members.
At Qubit Pharmaceuticals, Romain will lead the industrialization of the company’s technological foundation. This foundation relies on three main components:
-
Advanced expertise in high-performance computing hardware architecture
-
World-class quantum chemistry and artificial intelligence algorithms
-
An automated, cloud-native platform for molecular dynamics simulation and chemically accurate free energy calculations
The company recently announced the deployment of FeNNix-Bio1, the world’s most advanced AI foundation model for molecular simulation in pharmaceutical chemistry (see press release dated May 20, 2025). This technology stack supports the company’s internal drug discovery efforts but is also intended to power digital products that provide external users with access to cutting-edge capabilities.
Romain Delassus, Chief Information Officer at Qubit Pharmaceuticals
Robert Marino, CEO of Qubit Pharmaceuticals, stated: “We are delighted to welcome Romain Delassus to our team. His academic background and diverse professional experience in the massive undertaking of digital transformation within the French government—spanning large-scale data management and the development of critical IT platforms—perfectly aligns with our current needs, especially as Qubit Pharmaceuticals enters a new and promising phase with the launch of FeNNix-Bio1, our foundation model.”
Romain Delassus, Chief Information Officer of Qubit Pharmaceuticals, added: “After more than a decade working in public service, I’m excited to join Qubit Pharmaceuticals at such a strategic and dynamic moment for the company. FeNNix-Bio1 represents a paradigm shift in pharmaceutical chemistry and a major strategic pivot for Qubit. The challenge now is no longer just about incremental improvements in drug discovery—it’s about building a reference quantum model that stands out for its predictive power, robustness, and ability to address real-world use cases. My mission is to place product development at the heart of our research engine—not merely as its outcome, but as its driver.”
About Qubit Pharmaceuticals
Qubit Pharmaceuticals was founded in 2020 with the vision of co-developing safer, more effective new drugs in partnership with pharmaceutical and biotech companies. The company originated from the research of five internationally recognized scientists: Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St. Louis), and Pengyu Ren (University of Texas at Austin). Qubit Pharmaceuticals uses its Atlas platform to accelerate drug discovery through molecular simulation and modeling enhanced by hybrid HPC and quantum computing.
Its multidisciplinary team, led by CEO Robert Marino, is based in France at the Paris Santé Cochin incubator and in Boston, USA.
Qubit Pharmaceuticals was named a 2024 Technology Pioneer by the World Economic Forum and has established high-level partnerships with institutions such as Institut Curie, Sorbonne University, and the Institute of Pharmacology at the University of Sherbrooke in Canada.
For further information, including the drug discovery portfolio, visit www.qubit-pharmaceuticals.com
Press contacts
Ulysse Communication
Nicolas Daniels – ndaniels@ulysse-communication.com – +33 (0)6.66.59.22.63
Charles Courbet – ccourbet@ulysse-communication.com - + 33 (0)6.28.93.03.06
